Navigation Links
China Sky One Medical, Inc. Obtains SFDA Approval for Policresulen Vaginal Suppositories

HARBIN, China, March 12 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. (''China Sky One Medical'' or ''the Company'') (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China (''PRC''), today announced that it obtained approval from the State Food and Drug Administration (SFDA) in China for the production of Policresulen vaginal suppositories.

Policresulen vaginal suppositories are indicated for the treatment of cervical erosion, cervicitis, various vaginal inflammations resulting from bacteria, trichomoniasis or candidiasis, and for pressure ulcers due to vaginal pessary. The active ingredient in Policresulen vaginal suppositories is Policresulen, a topical haemostatic and antiseptic. This new product will be available to consumers around June of 2009.

''We are very pleased to receive SFDA approval in a timely manner, which continues to enable us to benefit from the increasing medical consumption in China tied to new health care reforms and a rising middle class,'' said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. ''We remain confident in our ability to identify drugs that have strong market potential that will enhance our portfolio.''

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company (''Jin Chuang'') the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915

SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China Pharma Holdings, Inc. to Host Fourth Quarter 2008 Earnings Conference Call at 8:30 a.m. EDT Wednesday March 18, 2009
2. China Yingxia International, Inc.s chairwoman and CEO is in talks with investors in China
3. China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date
4. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
5. China Shenghuo Announces Management Expansion and Enhanced Internal Controls
6. China Sky One Medical Inc. Gets SFDA Approval for Calcium Folinate Injection
7. China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16
8. University of the Rockies Faculty and Students Travel to China to Share Western Philosophy
9. QSAI & SGS-CSTC to Begin Joint Food Analysis Services in China
10. China Sky One Medical, Inc. Exports Sumei Slim Patch to South Korea and Sudan
11. China Healthcare Acquisition Announces Record Date for Trust Fund Distribution
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: